Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer. - Wikidata - awgldk - TriplyDB

Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer.

Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer.

http://www.wikidata.org/entity/Q34042831

about

Comparing the rules of engagement of androgen and glucocorticoid receptors Nfib Regulates Transcriptional Networks That Control the Development of Prostatic Hyperplasia Broad H3K4me3 is associated with increased transcription elongation and enhancer activity at tumor-suppressor genes.Targeting Androgen Receptor (AR)→IL12A Signal Enhances Efficacy of Sorafenib plus NK Cells Immunotherapy to Better Suppress HCC Progression.Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals.Genome-wide analysis reveals positional-nucleosome-oriented binding pattern of pioneer factor FOXA1.Androgen/androgen receptor axis maintains and promotes cancer cell stemness through direct activation of Nanog transcription in hepatocellular carcinoma.Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer.An Sp1 Modulated Regulatory Region Unique to Higher Primates Regulates Human Androgen Receptor Promoter Activity in Prostate Cancer Cells.Ligand-dependent genomic function of glucocorticoid receptor in triple-negative breast cancer.Androgen receptor activation: a prospective therapeutic target for bladder cancer?Rationale for the development of alternative forms of androgen deprivation therapy.Androgen receptor profiling predicts prostate cancer outcome.Alterations of androgen receptor-regulated enhancer RNAs (eRNAs) contribute to enzalutamide resistance in castration-resistant prostate cancer.Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression.Insights from resolving protein-DNA interactions at near base-pair resolution.Circular RNA expression is suppressed by androgen receptor (AR)-regulated adenosine deaminase that acts on RNA (ADAR1) in human hepatocellular carcinoma.Allosteric pathways in nuclear receptors - Potential targets for drug design.DNA Sequence Constraints Define Functionally Active Steroid Nuclear Receptor Binding Sites in Chromatin.Endogenous androgen receptor proteomic profiling reveals genomic subcomplex involved in prostate tumorigenesis.

P2860

Q33658855-5E27D3E3-1048-4643-8439-996F19246F2B Q36625094-68ED677B-84F5-485F-92E6-682C088407C8 Q36659374-A23803A9-69C0-4724-9D2C-EC4C0E10E53C Q36930091-8CD76674-01FC-4E38-ACD5-4D17129FBD14 Q36951558-73966A54-DDE9-43AF-8B31-A5871F70EB21 Q37264405-F3EA8DD7-BC2A-45BA-8B45-529B5EAA79FA Q37392841-898225F6-9280-4CD3-A80A-67B012DBD153 Q38673660-8AE773C9-46F7-49FF-BD1E-D7DA303D488D Q38829510-4C0A082E-34A5-4D7C-936F-D1E6E7427656 Q38835027-47B31801-8E9F-4657-8E73-F008EB2E318B Q39033724-99A1A0E8-D6F5-4592-994F-DFCDB71CB8C6 Q39342369-12685B6F-2AAA-4941-ABF3-A1443A990839 Q40493333-48CB0B7F-DF25-4343-8F13-A2D4EEBF458B Q41764330-709EF7AB-19A3-46E5-B3CB-25344B160A43 Q42013762-4D10F3A9-2703-4517-8D33-284064BC14C4 Q47323794-56B82299-3711-4090-8EAC-FABFDA6301E4 Q47586536-840D6196-0845-4FA2-9D31-89A0D7A32940 Q47591223-605E0F22-04BD-4201-A5EF-F0FF006364CE Q47699717-2AC6370A-5553-4389-9333-43DF91624BFD Q50026051-D8FB8557-8B11-4D34-AA28-81E83CD78EEA

P2860

Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer.

http://www.wikidata.org/entity/Q34042831

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Agonist and antagonist switch ...... n receptor in prostate cancer.

@ast

Agonist and antagonist switch ...... n receptor in prostate cancer.

@en

Agonist and antagonist switch ...... n receptor in prostate cancer.

@nl

type

label

Agonist and antagonist switch ...... n receptor in prostate cancer.

@ast

Agonist and antagonist switch ...... n receptor in prostate cancer.

@en

Agonist and antagonist switch ...... n receptor in prostate cancer.

@nl

prefLabel

Agonist and antagonist switch ...... n receptor in prostate cancer.

@ast

Agonist and antagonist switch ...... n receptor in prostate cancer.

@en

Agonist and antagonist switch ...... n receptor in prostate cancer.

@nl

P1433

Q34042831-7F427E5D-D2A1-41F4-884C-E0D4885B86E5

P1476

Q34042831-DA5F2C6D-7DF4-4469-AF10-3DB20C4BEFE8

P2093

Q34042831-016CCAF1-83C7-453D-A00E-B7E6B9CDF605

Q34042831-0C8C5C8A-0AF7-4FBB-8DCB-9BA620AB30DB

Q34042831-12A7D196-2A73-41A9-82FD-C86CCF932543

Q34042831-15A5AB6D-6C47-4545-BE2E-062FE7F8D1AF

Q34042831-191DD3D7-DD5C-44A6-9CE5-F4D45DED9782

Q34042831-1C2D394E-46C5-4A0D-BC37-CC6B178E5944

Q34042831-37303B57-BB01-4D73-B9EB-F801170F2B42

Q34042831-43D5FC5D-1DC2-4CEB-8C89-AF4A5FE0069D

Q34042831-4F6712CC-3EA6-4C52-8B37-A4C27929F1DA

Q34042831-6700FA6A-3ACF-4F1C-992C-45BCFF92025A

P2860

Q34042831-0DF0DF63-A446-4BC7-9C4D-3A134BCF1207

Q34042831-0EE8DB42-28DF-4D77-BB4E-8A94400231B1

Q34042831-10C724C8-EAF5-41A2-8BAC-B6967A463D4D

Q34042831-114E76AB-4B17-48D0-A9CC-3430E2A70F05

Q34042831-12E812D3-F12A-4E2B-B340-297890574A75

Q34042831-1824D56D-7EC6-4F7B-AC8D-95D62173080F

Q34042831-2210C826-02D4-4064-881C-BDA41CAD6A09

Q34042831-2464F9BD-8761-4852-9EFA-57EE5F534C72

Q34042831-28776481-A3C6-4456-9FFE-7410467E1862

Q34042831-3A70E0DB-F2B2-49CA-B650-507880771D00

P304

Q34042831-744B168D-C34A-46CF-A11A-FF8A884367C0

P31

Q34042831-78B27D49-BA07-4564-8616-748417ADB39A

P356

Q34042831-08787A26-C41F-4452-976B-D6B20249F107

P407

Q34042831-2F535326-CA3D-44BF-A6B3-E2A690534540

P433

Q34042831-A787C5E2-90D3-48E9-9CA1-5E5FF99D89E9

P478

Q34042831-5EA6C29C-A34D-4C6B-A96E-F9A96FC35B68

P577

Q34042831-8E3F7AEE-2A77-46A3-938E-F74D7EA50133

P5875

Q34042831-7087DDC0-DE29-454F-BA3C-EF56004AD116

P698

Q34042831-D0B1794B-BFFB-49FF-9C41-0E611886CC1E

P932

Q34042831-8304CA47-F5DF-47A6-AC27-C6BDDE830793

P356

P1433

The EMBO Journal

P1476

Agonist and antagonist switch ...... n receptor in prostate cancer.

@en

P2093

Benjamin Sunkel

http://www.w3.org/2001/XMLSchema#string

Cassandra Grenade

http://www.w3.org/2001/XMLSchema#string

Dayong Wu

http://www.w3.org/2001/XMLSchema#string

Debra L Zynger

http://www.w3.org/2001/XMLSchema#string

Jennifer M Thomas-Ahner

http://www.w3.org/2001/XMLSchema#string

Jiaoti Huang

http://www.w3.org/2001/XMLSchema#string

Junsheng Chen

http://www.w3.org/2001/XMLSchema#string

Kenneth P Nephew

http://www.w3.org/2001/XMLSchema#string

Liguo Wang

http://www.w3.org/2001/XMLSchema#string

Pearlly S Yan

http://www.w3.org/2001/XMLSchema#string

P2860

Differential oestrogen receptor binding is associated with clinical outcome in breast cancer

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

Structure of the intact PPAR-gamma-RXR- nuclear receptor complex on DNA

DNA Binding Site Sequence Directs Glucocorticoid Receptor Structure and Activity

Multidomain integration in the structure of the HNF-4α nuclear receptor complex

A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.

The nuclear receptor superfamily: the second decade

Overcoming mutation-based resistance to antiandrogens with rational drug design

DNA-binding specificities of human transcription factors

Androgen receptor in prostate cancer

P304

502-516

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.15252/EMBJ.201490306

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P577

2014-12-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

269936711

http://www.w3.org/2001/XMLSchema#string

P698

25535248

http://www.w3.org/2001/XMLSchema#string

P932

4331004

http://www.w3.org/2001/XMLSchema#string